×

J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion

By Thomson Reuters Nov 16, 2026 | 7:15 AM

Nov 16 (Reuters) – Johnson & Johnson said on Monday it had agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion, expanding its pipeline of eye disease therapies.

The drugmaker ​said it would acquire Ollin for $2.2 billion upfront, with ‌the potential for regulatory and commercial milestone payments of up to about $1.13 billion.

Ollin, backed by investment firms ARCH Venture Partners and Mubadala Capital, was established in 2023 to develop treatments for vision-threatening diseases.

Through the deal, J&J will gain access ‌to ​an experimental eye disease treatment, expanding its ⁠presence in a therapeutic ⁠area where it has a limited footprint despite its large contact lens business.

Ollin is developing OLN324, an experimental drug to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD), two leading ​causes of vision loss.

“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more ⁠sustained disease control,” said Kip Connor, vice ⁠president, ophthalmology disease area stronghold leader, Johnson & Johnson.

In ​a recent early-stage head-to-head study, the drug showed faster and greater improvements ​in eye structure and greater vision gains in both ‌DME and wet AMD than Roche’s Vabysmo, Ollin said.

Its pipeline also includes OLN102, currently in preclinical development for thyroid eye disease and Graves’ disease.

The biotech has said it plans to begin late-stage studies testing ⁠OLN324 in the second half of this year, and raised $330 million in June to fund the trials.

The deal is expected to close before ⁠the end of 2026.

J&J ‌said it would also enter into a separate ⁠agreement with Blackstone Life Sciences. Blackstone will pay $750 ​million ‌to the drugmaker over multiple years to fund ​the late-stage ⁠development of OLN324 and will, in turn, be eligible to receive payments and royalties.

Last week, Pfizer said Blackstone would provide up to $1.5 billion through 2028 to help fund the development of an experimental monthly obesity treatment.

(Reporting by Sneha S K in Bengaluru; Editing by Anil D’Silva ​and Joyjeet Das)